Biogen Settles Investors' $50M Claim Over Pain Drug Deal
Shareholders have settled their dispute with U.K.-based drug company Biogen for allegedly failing to make a $50 million payment under a deal to acquire the company and its nerve pain medication,...To view the full article, register now.
Already a subscriber? Click here to view full article